Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Can-Fite Pharmaceuticals (CANF) has completed patient enrollment for an interim analysis in its Phase 3 psoriasis trial, representing a significant clinical development milestone for the small-cap biotech firm. The completion of enrollment signals operational execution and validates the trial's viability at interim checkpoint, a prerequisite for regulatory pathway progression.

The interim analysis protocol has been agreed upon by both the FDA and EMA, establishing regulatory alignment before data readout. This dual-agency agreement de-risks the trial design and suggests favorable preliminary discussions with regulators. Data delivery is expected in Q4 2026 or Q1 2027, providing a concrete catalyst window for market reassessment.

For a micro-cap biotech, enrollment completion is typically a positive signal, reducing execution risk and demonstrating patient recruitment feasibility in the psoriasis indication. However, interim data represents only a snapshot; full Phase 3 completion remains 12–24 months away. Success probability in late-stage dermatology programs varies materially.

Sector implication: This development positions CANF within the Health Care innovation segment, where clinical milestones generate elevated volatility and binary outcomes. The news carries limited broad-market correlation but heightens sector sentiment toward late-stage biotech catalysts and immunological therapeutic advancement.